News & Updates

Obesity and overweight are now among the most pervasive health challenges worldwide, contributing substantially to the burden of cardiovascular disease (CVD). In Singapore, the 2022 National Population Health Survey reported that one in nine adults is obese, while nearly a third are overweight—a trend that continues to climb. [https://isomer-user-content.by.gov.sg/3/28c3b8f9-9216-46be-8fc9-b614098666a9/nphs-2022-survey-report_final.pdf]

The use of bemarituzumab in combination with chemotherapy provides statistically significant survival benefits among patients with advanced or metastatic FGFR2b-overexpressing gastric or gastroesophageal junction cancer (G/GEJC) in the primary analysis of the phase III FORTITUDE-101 trial.

First-line treatment with datopotamab deruxtecan (Dato-DXd) results in statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) compared with chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), as shown by the results of the phase III TROPION-Breast02 trial.

An updated analysis of MARIPOSA reveals significant reductions in the incidence of MET and EGFR resistance alterations with first-line amivantamab plus lazertinib compared with osimertinib, with no upregulation in other resistance pathways, in patients with nonsmall cell lung cancer (NSCLC).